Contamination of Arizona crematory raises questions of how to manage postmortem radiopharmaceuticals

The body of a 69-year-old male patient treated with lutetium-177 dotate contaminated an Arizona crematorium after radioactive material was found on equipment there, Tech Times reported. The incident has raised questions about the postmortem management of radiopharmaceuticals.

The case study, published in JAMA, found traces of radioactivity on the vacuum filter, oven and bone crusher of the crematory. A radioactive compound unrelated to the deceased man was found in the urine of an employee, which lead author Nathan Yu, of the department of radiation oncology at the Mayo Clinic, believes was due to cremating other remains.

While the authors don’t believe workers were exposed to dangerous doses of radiation, there are no federal regulations on how to care for bodies of patients who were exposed to radioactive materials following medical treatment, the Times reported.

"Future safety protocols for radiopharmaceuticals should include postmortem management, such as evaluating radioactivity in deceased patients prior to cremation and standardizing notification of crematoriums,” Yu and colleagues, wrote.

Read the entire story below.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.